GEMPHIRE THERAPEUTICS INC. FOURTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND CONVERTIBLE PROMISSORY NOTESNote Purchase Agreement and Convertible Promissory Notes • June 13th, 2016 • Gemphire Therapeutics Inc. • Pharmaceutical preparations
THIS FOURTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND CONVERTIBLE PROMISSORY NOTES (this “Fourth Amendment”) is made effective as of this 26th day of April 2016 (the “Fourth Amendment Date”), by and among GEMPHIRE THERAPEUTICS INC., a Delaware corporation (the “Company”), and the purchasers of the Company’s Convertible Promissory Notes identified on the signature page attached hereto (the “Purchasers”).
OMNIBUS AMENDMENT TO NOTE PURCHASE AGREEMENT AND CONVERTIBLE PROMISSORY NOTESNote Purchase Agreement and Convertible Promissory Notes • July 1st, 2019 • ChromaDex Corp. • Medicinal chemicals & botanical products • New York
This Omnibus Amendment to Note Purchase Agreement and Convertible Promissory Notes (this “Amendment”), dated as of June 30, 2019 (the “Effective Date”), by and among ChromaDex Corporation, a Delaware corporation (the “Company”), and the note holders identified on the signature pages hereto (the “Holders”), amends and modifies (i) that certain Note Purchase Agreement, dated May 9, 2019, by and among the Company and the Holders (as it may be amended from time to time, the “Purchase Agreement”) and (ii) the Convertible Promissory Notes issued by the Company to the Holders pursuant to the Purchase Agreement (the “Notes”).
